{"url_path":"/sec/vyne/8-k/2026-05-21/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-065214-index.html","accession_number":"0001104659-26-065214","cik":"0001566044","ticker":"VYNE","issuer_name":"Yarrow Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-065214-index.html","primary_entity_key":"0001566044","primary_entity_name":"VYNE Therapeutics Inc."},"word_count":727,"has_tables":true,"body_markdown":"**Item 7.01**\n**Regulation FD Disclosure.**\n\n \n\nOn May 21, 2026, Yarrow Bioscience, Inc. (“Yarrow”)\npublished an investor presentation (the “Presentation”) that it plans to use for investor relations and other purposes. VYNE\nTherapeutics Inc. (“VYNE”) has also made the Presentation available on the Investor portion of its website at https://vynetherapeutics.com/investors-media/events_presentations/\nA copy of the Presentation is attached as Exhibit 99.1.\n\n \n\nThe information in this Item 7.01 and Exhibit 99.1 hereto is being\nfurnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the\n“Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference\nin any of VYNE’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific\nreference in such filing.\n\n \n\n**No Offer or Solicitation**\n\n \n\nThis Current Report on Form\n8-K and the exhibit furnished herewith are not intended to and do not constitute (i) a solicitation of a proxy, consent or approval with\nrespect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe\nfor or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there\nbe any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be\nmade except by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom. Subject to certain exceptions\nto be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly,\nin or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by\nany means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign\ncommerce, or any facility of a national securities exchange, of any such jurisdiction.\n\n \n\nNEITHER THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE “SEC”)\nNOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM 8-K AND\nTHE EXHIBIT FURNISHED HEREWITH ARE TRUTHFUL OR COMPLETE.\n\n \n\n \n\n \n\n** **\n\n**Important Additional Information About the Proposed Transaction\nHas Been Filed with the SEC**\n\n \n\nThis Current Report on Form\n8-K does not substitute for the S-4 (as defined below), proxy statement/prospectus or for any other document that VYNE has filed or may\nfile with the SEC in connection with the proposed transaction. In connection with the proposed transaction between VYNE and Yarrow, VYNE\nhas filed relevant materials with the SEC, including a registration on Form S-4 (File No.: 333-294804) that contains a proxy statement/prospectus\n(the “S-4”). VYNE URGES INVESTORS AND STOCKHOLDERS TO READ THE S-4, INCLUDING THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN,\nAND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY\nAND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT VYNE, YARROW, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors\nand stockholders will be able to obtain free copies of the S-4 and other documents filed by VYNE with the SEC through the website maintained\nby the SEC at *www.sec.gov*. In addition, investors and stockholders should note that VYNE communicates with investors and the public\nusing its website (*www.vynetherapeutics.com*) and the investor media website (*https://vynetherapeutics.com/investors-media*)\nwhere anyone will be able to obtain free copies of the S-4 and included proxy statement/prospectus and other documents filed by VYNE with\nthe SEC and stockholders are urged to read the S-4 and included proxy statement/prospectus and the other relevant materials before making\nany voting or investment decision with respect to the proposed transaction.\n\n \n\n**Participants in the Solicitation**\n\n \n\nVYNE, Yarrow and their respective\ndirectors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with\nthe proposed transaction. Information about VYNE’s directors and executive officers, including a description of their interests\nin VYNE, is included in the S-4 and VYNE’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with\nthe SEC on February 27, 2026. These documents are available free of charge at the SEC's web site at www.sec.gov."}